Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal
- PMID: 2060570
- DOI: 10.1007/BF00315215
Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal
Abstract
The systemic availability of oral zidovudine has been studied in 13 patients with the acquired immunodeficiency syndrome (AIDS) dosed either fasting or with breakfast. The mean peak plasma concentration and AUC of zidovudine were significantly 2.8- and 1.4-times higher in fasting patients than in those treated during meal. In both conditions the mean half-life was about 1.5 h and the period of plasma zidovudine concentrations greater than 1 mumol.l-1 was 2 h (NS). It is concluded that if zidovudine is taken on an empty stomach, high peak plasma concentrations and decreased variation in pharmacological parameters may be expected. Whether or not this will influence toxicity and efficacy remains to be shown.
Similar articles
-
Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.Antimicrob Agents Chemother. 1993 Oct;37(10):2153-8. doi: 10.1128/AAC.37.10.2153. Antimicrob Agents Chemother. 1993. PMID: 8257138 Free PMC article. Clinical Trial.
-
Absorption of zidovudine in patients with diarrhoea.Eur J Clin Pharmacol. 1993;44(5):501-3. doi: 10.1007/BF00315553. Eur J Clin Pharmacol. 1993. PMID: 8359192
-
Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal.AIDS. 1990 Mar;4(3):229-32. doi: 10.1097/00002030-199003000-00008. AIDS. 1990. PMID: 2350441 Clinical Trial.
-
Zidovudine for the treatment of HIV infection.Am Fam Physician. 1990 Aug;42(2):437-43. Am Fam Physician. 1990. PMID: 2200250 Review.
-
Clinical pharmacokinetics of zidovudine. An update.Clin Pharmacokinet. 1996 Apr;30(4):251-62. doi: 10.2165/00003088-199630040-00001. Clin Pharmacokinet. 1996. PMID: 8983858 Review.
Cited by
-
Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity.Eur J Clin Pharmacol. 1993;45(5):397-407. doi: 10.1007/BF00315509. Eur J Clin Pharmacol. 1993. PMID: 8112367 Clinical Trial.
-
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.Antimicrob Agents Chemother. 2001 Jan;45(1):236-42. doi: 10.1128/AAC.45.1.236-242.2001. Antimicrob Agents Chemother. 2001. PMID: 11120972 Free PMC article. Clinical Trial.
-
Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses.AIDS Behav. 2023 May;27(5):1441-1468. doi: 10.1007/s10461-022-03880-6. Epub 2022 Nov 1. AIDS Behav. 2023. PMID: 36318429 Free PMC article.
-
Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.Clin Pharmacokinet. 1996 Apr;30(4):314-27. doi: 10.2165/00003088-199630040-00004. Clin Pharmacokinet. 1996. PMID: 8983861 Review.
-
The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients.Br J Clin Pharmacol. 1992 Jun;33(6):657-60. doi: 10.1111/j.1365-2125.1992.tb04097.x. Br J Clin Pharmacol. 1992. PMID: 1389940 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous